Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant for CINV in Chinese NSCLC patients
NCT02161991Phase 3Completed
- Sponsor
- Hunan Cancer Hospital
- Start
- Feb 2014
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Hunan Cancer Hospital. Primary endpoint: Complete response rate of chemotherapy-induced nausea and vomiting at 6 months. Started Feb 2014; status: completed.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT02161991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02161991.